Vernalis plc Company Profile (LON:VER)

About Vernalis plc (LON:VER)

Vernalis plc logoVernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: LON:VER
  • CUSIP: N/A
  • Web:
  • Market Cap: £66.46 million
  • Outstanding Shares: 526,445,000
Average Prices:
  • 50 Day Moving Avg: GBX 14.79
  • 200 Day Moving Avg: GBX 17.83
  • 52 Week Range: GBX 10 - GBX 39.34
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £21.3 million
  • Price / Sales: 3.12
  • Book Value: GBX 0.16 per share
  • Price / Book: 0.80
  • EBITDA: ($24,870,000.00)
  • Net Margins: -69.02%
  • Return on Equity: -23.94%
  • Return on Assets: -20.89%
  • Average Volume: 248,847 shs.

Frequently Asked Questions for Vernalis plc (LON:VER)

What is Vernalis plc's stock symbol?

Vernalis plc trades on the London Stock Exchange (LON) under the ticker symbol "VER."

How were Vernalis plc's earnings last quarter?

Vernalis plc (LON:VER) posted its earnings results on Tuesday, September, 12th. The company reported ($4.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.50) by $0.40. The business had revenue of $20.79 million for the quarter. Vernalis plc had a negative net margin of 69.02% and a negative return on equity of 23.94%. View Vernalis plc's Earnings History.

Where is Vernalis plc's stock going? Where will Vernalis plc's stock price be in 2017?

6 brokerages have issued 1-year price targets for Vernalis plc's stock. Their forecasts range from GBX 21 to GBX 88. On average, they anticipate Vernalis plc's share price to reach GBX 39.40 in the next twelve months. View Analyst Ratings for Vernalis plc.

Who are some of Vernalis plc's key competitors?

Who are Vernalis plc's key executives?

Vernalis plc's management team includes the folowing people:

  • Ian R. Garland, Chief Executive Officer, Executive Director
  • David Mackney, Chief Financial Officer, Executive Director
  • Kevin Kissane, Company Secretary
  • Peter J. Fellner, Non-Executive Chairman of the Board
  • Ian David Gilham Ph.D., Non-Executive Director
  • Lisa Amster Schoenberg, Non-Executive Director
  • Carol C. Ferguson, Senior Independent Non-Executive Director
  • Nigel Sheail, Non-Executive Independent Director

How do I buy Vernalis plc stock?

Shares of Vernalis plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Vernalis plc's stock price today?

One share of Vernalis plc stock can currently be purchased for approximately GBX 12.63.

MarketBeat Community Rating for Vernalis plc (LON VER)
Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about Vernalis plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vernalis plc (LON:VER) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: GBX 39.40
Consensus Price Target History for Vernalis plc (LON:VER)
Price Target History for Vernalis plc (LON:VER)
Analysts' Ratings History for Vernalis plc (LON:VER)
DateFirmActionRatingPrice TargetDetails
8/7/2017Panmure GordonReiterated RatingHoldGBX 31View Rating Details
8/7/2017Stifel NicolausLower Price TargetHoldGBX 24 -> GBX 21View Rating Details
8/7/2017RX SecuritiesReiterated RatingBuyView Rating Details
8/7/2017N+1 SingerReiterated RatingHoldGBX 28View Rating Details
4/21/2017Numis Securities LtdReiterated RatingAddGBX 29View Rating Details
2/14/2017Canaccord GenuityReiterated RatingBuyGBX 88View Rating Details
12/21/2016Shore CapitalReiterated Ratinghouse stockView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Vernalis plc (LON:VER)
Earnings by Quarter for Vernalis plc (LON:VER)
Earnings History by Quarter for Vernalis plc (LON VER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/12/2017Y 2017GBX (4.50)GBX (4.10)GBX 2,079 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vernalis plc (LON:VER)
Current Year EPS Consensus Estimate: $-5.570 EPS


Dividend History for Vernalis plc (LON:VER)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vernalis plc (LON:VER)
Insider Trades by Quarter for Vernalis plc (LON:VER)
Insider Trades by Quarter for Vernalis plc (LON:VER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/12/2016David MackneyInsiderSell27,233GBX 39£10,620.87
9/30/2016Carol FergusonInsiderBuy28,000GBX 41£11,480
6/9/2016Mackney,DavidInsiderBuy97,000GBX 45£43,650
5/5/2015Nigel SheailInsiderBuy84,000GBX 59.90£50,316
(Data available from 1/1/2013 forward)


Headline Trends for Vernalis plc (LON:VER)
Latest Headlines for Vernalis plc (LON:VER)
DateHeadline logoVernalis plc (VER) Receives Consensus Recommendation of "Hold" from Analysts - October 19 at 2:36 PM logoVernalis plc (VER) Given Average Rating of "Hold" by Brokerages - September 24 at 3:10 PM logoVernalis Plc :VER-GB: Earnings Analysis: For the six months ended June 30, 2017 : September 21, 2017 - September 23 at 10:41 AM logoVernalis Plc :VER-GB: Earnings Analysis: 2017 By the Numbers : September 18, 2017 - September 19 at 9:19 AM logoSignificant Milestones Drive Vernalis' Revenue Above Expectations - London South East (registration) (blog) - September 13 at 3:48 PM logoVernalis plc (VER) Announces Earnings Results, Beats Expectations By $0.40 EPS - September 12 at 12:44 PM logoVernalis plc (VER) Posts Earnings Results, Misses Estimates By $4.06 EPS - September 12 at 12:28 PM logoVernalis plc: Results Announcement for the year ended 30 June 2017 - September 12 at 11:50 AM logoVernalis plc (VER) Given Average Rating of "Hold" by Analysts - August 30 at 2:32 PM logoVernalis plc (LON:VER) Stock Rating Reaffirmed by Panmure Gordon - August 7 at 12:34 PM logoVernalis plc (VER) Price Target Lowered to GBX 21 at Stifel Nicolaus - August 7 at 12:34 PM logoRX Securities Reaffirms Buy Rating for Vernalis plc (LON:VER) - August 7 at 12:34 PM logoFDA Flags Questions Over Vernalis's CCP-08 New Drug Application - August 7 at 8:20 AM logoVernalis PLC: FDA Issues Complete Response Letter on CCP-08 NDA - August 7 at 8:20 AM logoVernalis plc (VER) Receives Consensus Recommendation of "Hold" from Brokerages - August 5 at 2:38 PM logoVernalis Expects Annual Revenue Ahead Of Market Consensus - London South East (registration) (blog) - July 19 at 9:01 AM logoVernalis plc (LON:VER) Given Consensus Rating of "Hold" by Analysts - July 11 at 2:10 PM logoVernalis Partners With Servier On Oncology Drug-Discovery - March 6 at 11:47 AM logoBRIEF-Vernalis Plc enters drug discovery collaboration with Servier - March 6 at 11:47 AM logoUK Stocks-Factors to watch on Feb. 21 - February 21 at 4:23 PM logoHalf Year 2017 Vernalis PLC Earnings Release - Time Not Supplied - February 21 at 4:23 PM logoIs this small-cap value stock the next Shire plc? - February 21 at 4:23 PM


Social activity is not available for this stock.


Vernalis plc (VER) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.